- Sales revenue up 56.2 percent to 2,109 million euros; underlying EBITDA margin 36.3 percent
- Dynamic and profitable organic growth; significant demand momentum generated by the production of coronavirus vaccines as well as strong development of acquisitions
- Forecast raised at the beginning of July for 2021 confirmed
PR Newswire
AUBAGNE, France, Oct. 20, 2021